GeoVax Labs Gets BARDA Project Nextgen Award To Conduct Phase 2b Clinical Study Evaluating Next-Generation Covid-19 Vaccine Candidate, GEO-CM04S1; Direct Award To GeoVax Of ~$24.3M, Which May Increase To As Much As $45M
Portfolio Pulse from Benzinga Newsdesk
Geovax Labs has received a BARDA Project NextGen award to conduct a Phase 2b clinical study for its next-generation COVID-19 vaccine candidate, GEO-CM04S1. The direct award is approximately $24.3 million, with potential to increase to $45 million.
June 18, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geovax Labs has been awarded approximately $24.3 million by BARDA for a Phase 2b clinical study of its COVID-19 vaccine candidate, GEO-CM04S1. The funding may increase to $45 million.
The significant funding from BARDA for the Phase 2b clinical study of GEO-CM04S1 is a positive development for Geovax Labs. This financial support not only validates the potential of their vaccine candidate but also provides the necessary resources to advance its development. The potential increase in funding to $45 million further underscores the importance of this project. Investors are likely to view this news favorably, leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100